| Literature DB >> 31038950 |
Girdhar Singh Deora1, Cheng Xue Qin2,3, Elizabeth A Vecchio2, Aaron J Debono1, Daniel L Priebbenow1, Ryan M Brady1, Julia Beveridge1, Silvia C Teguh1, Minh Deo2, Lauren T May4, Guy Krippner2, Rebecca H Ritchie2,3,5, Jonathan B Baell6,1,7.
Abstract
Herein we describe the development of a focused series of functionalized pyridazin-3(2 H)-one-based formyl peptide receptor (FPR) agonists that demonstrate high potency and biased agonism. The compounds described demonstrated biased activation of prosurvival signaling, ERK1/2 phosphorylation, through diminution of the detrimental FPR1/2-mediated intracellular calcium (Cai2+) mobilization. Compound 50 showed an EC50 of 0.083 μM for phosphorylation of ERK1/2 and an approximate 20-fold bias away from Cai2+ mobilization at the hFPR1.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31038950 DOI: 10.1021/acs.jmedchem.8b01912
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446